551 results about "Disease patient" patented technology

The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.

The invention provides a method and a system for predicting cardiovascular and cerebrovascular disease risks. The method comprises the following steps: step 1, defining problems of cardiovascular and cerebrovascular disease prognosis risk prediction, step 2, collecting health medical data of cardiovascular and cerebrovascular disease patients; step 3, preprocessing data, including data integration, data cleaning, and processing missing data; step 4, constructing features and selecting features, identifying potential risk factors; step 5, the identified risk factors and rehabilitation outcomes forming an input-output sample set, inputting the input-output sample set to a random forest algorithm for model training, and evaluating prediction performance of a model. The method and the system can obtain health medical data of cardiovascular and cerebrovascular disease patients, the data being required by a clinician input model, and a predicted rehabilitation outcome of a patient in a certain time period in future is obtained through the model. The method and the system can preferably predict prognosis risks, so as to realize personalized accurate rehabilitation treatment.

AβN3pE-42 is a β amyloid protein that accumulates specifically as a major constituent of senile plaque in the brains of both sporadic and familial Alzheimer's disease patients. The invention provides antibodies that specifically recognize AβN3pE-42 and can be expected to have a strong β amyloid-removing action. Particularly, humanized antibodies against AβN3pE-42 are useful to treat human neurodegenerative diseases. Further, since AβN3pE-42 is localized in the brain, the antibodies of the invention can avoid side effects such as kidney disorders caused by the formation of antigen-antibody complex in the blood. An agent for gene therapy using a vector in which a cDNA encoding a protein comprises the antigen-binding region of the antibody can be an efficient therapeutic drug for removing β amyloid from the brain.

The invention relates to an artificial-intelligence exercise assisting device. The artificial-intelligence exercise assisting device is mainly used for lower-limb walking assisting and lower-limb rehabilitation training. According to the technical scheme, the artificial-intelligence exercise assisting device comprises a structure supporting system, sensors, sensor circuits, a signal processing system (a mobile calculation platform), a driving executing device, a power system and a walking stick. The artificial-intelligence exercise assisting device has the advantages that the dilemma that movement of the lower limbs of a paralysis patient, a hemiplegic paralysis patient, a fracture patient and an old bone joint retrogressive disease patient is inconvenient is overcome. A user wears an exoskeleton wearing assisting device, human body signals and the assisting device interact with each other and are matched, the human body transmits a control command to the exoskeleton wearing assisting device, exoskeleton detects the human body signals, a proper command is obtained after artificial intelligence calculation, then driving mechanisms provide energy required by movement for the lower limbs of the human body, and the finally the effect that artificial intelligent and mechanical force are supplemented and interacted is achieved. According to the artificial-intelligence exercise assisting device, the human body control signals and the artificial intelligence of a machine are fused, the balance of the gravity center of the human body is controlled, and mild control over the exoskeleton assisting device is obtained.

In a method for allowing a patient suffering from a neurological disease and being treated with medication to self-monitor his or her current state, information regarding the motor functions and / or verbal and / or cognitive abilities of the patient are interactively acquired upon using a computer located for easy and repeated access by the patient, and at least one criterion number or a statement describing the state is determined on the basis of this information by an expert system at the computer and is made available to the patient by an output device at the computer.

The invention discloses a method for processing head structure image data based on a deep learning algorithm. The method comprises the following steps of acquiring head magnetic resonance structure image data and storing the head magnetic resonance structure image data in a computer; first extracting corresponding features of multiple frames of pictures through convolutional neural network models respectively, then taking a feature of a sequence picture as a sequence input of an LSTM (Long Short-Term Memory) model, and taking combination of the feature of the sequence picture and a tag corresponding to a whole sequence as a training sample of the LSTM model; sequentially inputting 100 layers of pictures in the middle of an MRI (Magnetic Resonance Imaging) image by adopting 3 layers of LSTM models, wherein each layer of picture corresponds to a 1024-dimensional feature, and the end of the model is a full connection layer of two classifiers; importing to-be-analyzed medical data into a deep learning model to perform matched medical analysis; and when the model training is finished, arranging test samples in the same format as an MRI sequence layer, and then performing classification by using the trained deep learning model to judge whether the MRI image belongs to a smoker, a drug addict or a disease patient.

The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of depression in Alzheimer's disease and / or Parkinson's disease patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.

The present invention relates to compositions and methods to modulate alpha-secretase and / or to improve cognitive ability. The invention further relates the improved / enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).

A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson's disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline.

The present invention relates to a composition comprsing a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional / regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional / regulatory site of the Aβ peptide and generate antibodies, which are highly cross-reactive to the soluble Aβ1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble Aβ1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the “soluble Aβ-derived toxins”; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.

Systems and methods for assessment of sleep quality in adults and children are provided. These techniques include an apparatus worn above the forehead containing the circuitry for collecting and storing physiological signals. The apparatus integrates with a sensor strip and a nasal mask to obtain the physiological signals for the user. The form factor of this apparatus is comfortable, easy to self-apply, and results in less data artifacts than conventional techniques for capturing physiological data for analyzing sleep quality. Neuro-respiratory signals are analyzed using means to extract more accurate definitions of the frequency and severity of sleep discontinuity, sleep disordered breathing and patterns of sleep architecture.; Biological biomarkers and questionnaire responses can also be compared to a database of healthy and chronically diseased patients to provide a more accurate differential diagnosis and to help determine the appropriate disease management recommendations.

An integrated tele-health system / device for monitoring and reporting medical information for the evidence-based management of patients with chronic respiratory disease. The device includes a central unit which measures and collects information related to the state of health of the patient, and is provided with elements for wireless or cable transmission of the collected data using a microprocessor based system with a touch screen display, USB communication port and Bluetooth. The device further includes: a removable sensor for the measurement of respiratory air flow and volume, a removable pulse oximetry sensor and a motion sensor. Stored data can be then delivered through landline, broadband, wireless and cell-phone technology to be received by a web server and can then be accessed by medical staff. Being completely portable, the device is provided with a battery of known type, which can be substituted by the user or can be rechargeable.

Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded transgene product, thus allowing persistent transgene expression and repeated administration of the gene therapy product to the host. The present invention is also of relevance in genetic disease patients that mount immune responses to protein replacement therapies in which case the present invention provides for transient co-administration of rapamycin together with protein replacement therapy. In a further aspect of the invention, co-administration of rapamycin could inhibit a secondary immune response in a host that has been pre-immunized with the gene therapy vector or pre-immunized with the protein product encoded by the transgene.

The invention discloses a traditional Chinese medicine composition for the treatment of cervical spondylopathy and osteoarticular diseases and a preparation method thereof. The traditional Chinese medicine composition mainly consists of the following bulk drugs: cassia twig, Chinese angelica root, ledebouriella root, rhizome of Sichuan lovage, notopterygium, peppermint, root of kudzuvine, chrysanthemum flower, Chinese ephedra, capsule of weeping forsythia, dandelion, radix angelicae pubescentis, cortex moutan, lindera root, nutagrass flatsedge rhizome, auckandia root, red peony root, white peony root, root bark of barbary wolf berry, red sage root, tetrandra root, acanthopanax bark, bark of eucommia, achyranthis bidentatae, indian bread, magnolia bark, atractylodes rhizome, alisma rhizome, plantain seed, medicated leaven, atractylodes macrocephala, bark of chinese cassia tree, dried ginger, pricklyash berry, clove, curcuma root, corydalis tuber, safflower, peach kernel, motherwort, bighead atractylodes rhizome, raw milkvetch root, asiabell, glehnia root and boxthorn. The traditional Chinese medicine composition can obviously improve cervical spondylopathy and symptoms such as spondylopathy contraction, shoulder irritation, arthralgia, muscular tension, muscular fatigue, muscular acid bilge, dizziness, cephalalgia, soreness of the waist and the knees and pain in the legs and numbness of the extremities of other osteoarticular disease patients. The traditional Chinese medicine composition has stable efficacy, and moreover has advantages of quick effect, sustained effect, applicability to long-term use, low cost, no toxic-side effects and the like.

The invention relates to, among others, a method for assessing a prognosis of a patient with a malignant disease and / or for predicting the response of a patient with a malignant disease to immunotherapy. For this purpose, a DNA methylation analysis is carried out on at least one immunoregulatory gene of cells of the malignant disease and / or T lymphocytes which interact with the cells of the malignant disease, said gene coding for an immune checkpoint selected from B7 proteins and the receptors thereof, MHC-peptide complex-binding co-receptors, the members of the tumor necrosis factor receptorsuperfamily TNFRSF9, CD40, TNFRSF4, TNFRSF18, and CD27, the members of the immunoglobulin superfamily TIGIT, BTLA, HAVCR2, BTNL2, and CD48, and the andenosine-binding adenosine 2A receptor.

The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and / or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1 expression and detection of the presence of pANCA. Treatment methods include antigen-directed therapy targeting CBir1 flagellin and manipulating the bacteria in the colon and / or small intestine.

The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.

The invention discloses a plasma exosome circRNA marker for non-small cell lung cancer, as well as a detection primer and kit thereof. The circRNA marker is one or more of circ_0047921, circ_0007761,or circ_0056285. In a plasma exosome of an NSCLC patient, the expression level of the above-mentioned circRNAs is significantly different from that of plasma exosomes of other lung disease patients and healthy people. The invention also provides a specific primer group and a kit thereof for detecting circ_0047921, circ_0007761 and circ_ 0056285 respectively. The marker provided by the invention can be used alone in the diagnosis of NSCLC, and has certain accuracy, and a combination of the marker can significantly improve the accuracy of diagnosis (the AUC is 0.894, and the sensitivity and specificity are 87.25% and 80.00% respectively), and can differentiate NSCLC patients from other patients with lung diseases including pulmonary tuberculosis, chronic obstructive pulmonary disease and other disease patients, which is helpful to realize early detection of NSCLC.

The invention includes a high-through-put method of screening for a biomarker indicative of a disease, including the identification of a glycan alteration in a protein of a diseased patient. Further, the invention includes methods utilizing a microarray to measure the glycan level of a protein.

The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.

The invention provides a dendrobium polysaccharide extraction technology and product thereof and application. The production technology includes the following technological steps: smashing dendrobium (dry product) plant; adding water and mixing; adding cellulose enzyme; regulating pH value and enzymolysis; water extraction; concentration; alcohol precipitation stoving. Thus high purity dendrobium polysaccharide extract with the content reaching 21.7%. The dendrobium polysaccharide extract product contains dendrobium polysaccharide and additive. The dendrobium polysaccharide is made by the method; the additive is one of immune globulin, amino acid, traditional Chinese medicine, biology preparation, growth factor and various dairy (including infant formula milk powder) or combination thereof; and the product can be tablet, capsule and oral liquid. The mass percentage thereof is 15-85% for dendrobium polysaccharide and 15-85% for additive respectively. The effect includes that the invention can be applicable to: 1, people who frequently stay up late, cerebrate, use eyes, are irregular in work and rest, excessive in drink and tobacco and lack of energy; 2, people who are in life tension and under too much tension, take part in dinner party frequently and feel down in the doldrums frequently; 3, people who smoke, drink and take part in dinner party frequently; 4, diabetes mellitus and cardiovascular and cerebrovascular diseases patients who are not balanced in diet, like to eat meat or sweetmeats; 5, people who have low immunity, valetudinarianism, throat diseases, gastrointestinal disorders and cataract; 6, patients who have aeipathia and serious diseases and are subject to operation and cancer chemoradiotherapy. The additive of the final product of the invention is scientific and reasonable and has strong pertinence.

The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG.

The invention provides an Alzheimer's disease rehabilitation training and ability evaluation system based on virtual reality. The system comprises a rehabilitation training module, an ability evaluation module and a feedback module, wherein the rehabilitation training module is used for conducting rehabilitation training on an Alzheimer's disease patient in the aspects of cognition and social contact; the ability evaluation module is used for collecting the visual attention information, the behavior mode information and social communication ability information generated by the rehabilitation training module, carrying out comprehensive evaluation according to the information and generating a comprehensive evaluation result; and the feedback module is used for feeding back the evaluation result to the rehabilitation training module and changing the content and process of rehabilitation training. According to the invention, the behavior mode of the testee is amplified by using the virtualreality technology, the data is analyzed and processed by combining an artificial intelligence technology, a comprehensive evaluation result can be obtained by comparing the data with a standard control group and an Alzheimer's disease control group, and the content and process of rehabilitation training can be adjusted by combining real-time feedback and stage feedback to adapt to the current state of the Alzheimer's disease patient.

The invention relates to a microRNA standardization reference gene and an application thereof. Specifically, with Solexa sequencing, real-time fluorescence quantitative PCR detection, literature screening, statistical analysis methods, the invention carries out researches upon a large amount of samples collected from a healthy control group and different disease patients. As a result, microRNAs let-7d, let-7g, let-7i, or combinations thereof can serve as microRNA standardization housekeeping gene. Compared with reference genes (such as U6, RNU44, RNU48 and miR-16, and the like) most commonly used in current microRNA quantification, the microRNA standardization reference gene has high stability and accuracy.

The invention discloses a method for recording the movement of a slow disease patient and follow-up visit. The method comprises the following steps: (1) sending patient data to a Web server through a wireless network by a user terminal; (2) storing the received patient data with a file according to an appointed route by the Web server; and (3) after an inquiry command of the user terminal is received by the Web server, reading the patient data from the file according to the appointed route, and sending to the user terminal through the wireless network. The follow-up visit data of the patient and the measured data of physiological and biochemical parameters of human health are recorded with a mobile terminal by the patient for a long time, the follow-up visit data and the measured data form a human health file of the patient to be stored in the Web server, and a doctor uses the mobile terminal to consult the human health file of the patient and provide rehabilitation guidance through E-mails of the system, so that the patient record and doctor follow-up visit are performed in the same system.

A gait management apparatus applies stimulation to a user suffering from a neurological disease (such as Parkinson's Disease) gait dysfunction. Motion sensors are arranged to be worn by a patient, and electrical stimulation electrodes are on the legs for stimulation. A controller receives motion sensing signals, and processes these signals to generate stimulation signals for operation of the electrodes to stimulate limb movement upon detection of a gait abnormality. There may be a user actuator for user actuation of electrical stimulation, and the inputs may be a series of taps. The controller may provide signals to prevent occurrence of freezing of gait when it senses that a patient is walking or has an intention to walk. Also, it may apply stimulation at an intensity level which is insufficient for functional muscle stimulation but sufficiently high to trigger activation of efferent nerves.

This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg / day.

The invention belongs to the biotechnology application field, and relates to simultaneous detection and genotyping of infections of 16 respiratory viruses (including FluA, FluB, sH1N1, PIV1, PIV2, PIV3, RSVA, RSVB, HRV, HMPV, HBoV, CoV NL63, CoV OC43, CoV 229E, CoV HKU1 and Adv) of nasopharyngeal extract specimens of patients of respiratory-related diseases of all levels of disease prevention and control institutions and sentinel hospitals. Specifically, nucleotide sequences of representative strains of the 16 respiratory viruses are downloaded from NCBI; through literature review and multiple sequence alignment, pathogen relatively-conservative regions are determined, and multiplex specific primers are designed. Single-tube multiplex (18 stages) PCR detection is carried out for detecting the 16 respiratory virus conservative regions, and an entire reaction takes less than 2 hours. According to the invention, a defect that genotyping cannot be carried out with conventional single-tube multiplex fluorescent qualitative PCR detections can be overcome, and defects of complicated operations, long time, and high cost of conventional chip detection methods can be overcome. With the application provided by the invention, a novel idea is provided for respiratory virus genotyping technologies. With characteristics of high specificity, high sensitivity, and high speed, powerful technological support is provided for rapid and accurate screening and genotyping of the respiratory-disease-related viruses. The invention has important significance upon the researches of respiratory-tract patient infection pathogen spectrum of out nation, and upon molecular epidemiological investigations.